CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

CARsgen Expanded Collaboration with Shanghai Cancer Institute to Enhance Scientific and Technological Transformation

CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR T cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR T cells

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR T cells (CT053) for the Treatment of Multiple Myeloma

CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody

CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma